The value of the dental impaction pain model in drug development

• Published in: Methods in molecular biology (Clifton, N.J.) Vol. 617; p. 175
• Main Authors: Cooper, Stephen A, Desjardins, Paul J
• Format: Journal Article
• Language: English
• Published: United States 01.01.2010
• Subjects: Acetaminophen - therapeutic use; Analgesics, Non-Narcotic - therapeutic use; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Drug Design; Humans; Mefenamic Acid - therapeutic use; Models, Biological; Pain - drug therapy; Pain Measurement - methods; Pain Threshold; Pain, Postoperative - drug therapy; Placebos; Reproducibility of Results; Sensitivity and Specificity; Tooth, Impacted - drug therapy; Tooth, Impacted - physiopathology
• ISSN: 1940-6029
• DOI: 10.1007/978-1-60327-323-7_15

The modern version of the Dental Impaction Pain Model (DIPM) was developed in the mid-1970s. Since that time, several hundred studies have been conducted by numerous investigators. Today it is arguably the most utilized of all the acute pain models. Its popularity is due to the success rate of the studies, fast subject entry, and cost effectiveness. The surgical procedure is extremely standardized, and the surgery requires either minimal or no use of CNS depressant anesthetics. The methodology is similar to that utilized in other acute pain models; however, the DIPM is much more versatile than most other models. The model can be easily adapted to perform multiple-dose studies, pharmacokinetics/pharmacodynamics (PK/PD) correlations, preemptive interventions, and sleep-pain studies. A few investigators have even developed microdialysis techniques, wherein they insert probes into extraction sockets to collect exudates for measuring biochemical mediators of pain or drug levels at the site of injury. In many instances, an accomplished site can complete a study of several hundred subjects in approximately 3 months. There are studies in the literature that have incorporated up to six treatment arms in one study and clearly separated the drugs from each other. The exquisite assay sensitivity is due to the homogeneity of the study population, the predictable level and appropriate intensity of the postsurgical pain, and the minimizing of variability by using only one or two study centers. The DIPM has been employed to evaluate NSAIDs (both nonselective and selective Cox inhibitors), opioids and combination analgesics, as well as some investigational drugs with unique mechanisms of action. The model is particularly useful for proof-of-concept studies that require dose-ranging and profiling the time-effect curve for efficacy including onset, peak effect, and duration of analgesic activity.